TLR agonists have emerged as an efficient cancer vaccine adjuvant system that induces robust immune responses. L-pampo™, a proprietary vaccine adjuvant of TLR2 and TLR3 agonists, promotes strong humoral and cellular immune responses against infectious diseases. In this study, we demonstrate that vaccines formulated with L-pampo™ affect the recruitment and activation of dendritic cells (DCs) in draining lymph nodes (dLNs) and leading to antigen-specific T-cell responses and anti-tumor efficacy. We analyzed DC maturation and T-cell proliferation using flow cytometry and ELISA. We determined the effect of L-pampo™ on DCs in dLNs and antigen-specific T-cell responses using flow cytometric analysis and the ELISPOT assay. We employed murine tumor models and analyzed the anti-tumor effect of L-pampo™. We found that L-pampo™ directly enhanced the maturation and cytokine production of DCs and, consequently, T-cell proliferation. OVA or OVA peptide formulated with L-pampo™ promoted DC migration into dLNs and increased activation markers and specific DC subsets within dLNs. In addition, vaccines admixed with L-pampo™ promoted antigen-specific T-cell responses and anti-tumor efficacy. Moreover, the combination of L-pampo™ with an immune checkpoint inhibitor synergistically improved the anti-tumor effect. This study suggests that L-pampo™ can be a potent cancer vaccine adjuvant and a suitable candidate for combination immunotherapy.
TLR激动剂已成为一种能够诱导强烈免疫反应的高效癌症疫苗佐剂系统。L-pampo™作为TLR2和TLR3激动剂的专有疫苗佐剂，能促进针对传染病的强大体液和细胞免疫应答。本研究证明，采用L-pampo™制备的疫苗可影响引流淋巴结中树突状细胞的募集与活化，进而引发抗原特异性T细胞反应并产生抗肿瘤疗效。我们通过流式细胞术和ELISA技术分析了树突状细胞的成熟与T细胞增殖情况，并利用流式细胞分析和ELISPOT实验检测了L-pampo™对引流淋巴结中树突状细胞及抗原特异性T细胞反应的作用。通过建立小鼠肿瘤模型，我们评估了L-pampo™的抗肿瘤效果。研究发现，L-pampo™能直接促进树突状细胞成熟及细胞因子分泌，从而增强T细胞增殖能力。采用L-pampo™配制的OVA蛋白或OVA多肽可促进树突状细胞向引流淋巴结迁移，并提高淋巴结内活化标志物水平及特异性树突状细胞亚群数量。此外，含L-pampo™的疫苗能显著增强抗原特异性T细胞反应并提升抗肿瘤疗效。值得注意的是，L-pampo™与免疫检查点抑制剂的联合应用可协同增强抗肿瘤效果。本研究提示L-pampo™是一种高效的癌症疫苗佐剂，可作为联合免疫治疗的理想候选方案。
肿瘤(癌症)患者之家